Last updated on July 2018

A Study of ABBV-428 an Immunotherapy in Subjects With Advanced Solid Tumors

Brief description of study

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.

Clinical Study Identifier: NCT02955251

Contact Investigators or Research Sites near you

Start Over


Institut Gustave Roussy /ID# 162257
Villejuif, France
  Connect »